Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS withdrawal · 2016-03-31

Clinical Trial Update: Evaluation the Pharmacokinetics, Safety, Tolerability of BCD-021 in Patients With Neovascular Age-related Macular Degeneration [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating pharmacokinetics, safety, and tolerability of BCD-021 in patients with neovascular age-related macular degeneration has been withdraw…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BCD-021

Snippet

Sponsor: Biocad | Conditions: Neovascular Age-related Macular Degeneration | Phase 1 | Status: WITHDRAWN